Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anacetrapib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP known ✓ | P11597 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anacetrapib SCHEMBL29807658 | 1.00 | CETP (1.00) | CETPNR1I2 | |
| Anacetrapib SCHEMBL18432840 | 1.00 | CETP (1.00) | CETPNR1I2 | |
| Anacetrapib SCHEMBL22281463 | 1.00 | CETP (1.00) | CETPNR1I2 | |
| Anacetrapib SCHEMBL19229665 | 1.00 | CETP (1.00) | CETPNR1I2 | |
| Anacetrapib SCHEMBL9992680 | 1.00 | CETP (1.00) | CETPNR1I2 | |
| SCHEMBL21706772 | 0.96 | CETP (0.92) | CETPNR1I2 | |
| SCHEMBL25987747 | 0.96 | CETP (0.92) | CETPNR1I2 | |
| SCHEMBL17366580 | 0.95 | CETP (0.91) | CETPNR1I2 | |
| Anacetrapib SCHEMBL14016058 | 0.95 | CETP (0.91) | CETPNR1I2 | |
| SCHEMBL10242813 | 0.95 | CETP (0.91) | CETPNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 979 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-12150975-B2 | Therapeutic combinations to treat red blood cell disorders | HARTIS-PHARMA SA (CH) | 2024-11-26 | — | — | US | claimed |
| US-11549142-B2 | CETP inhibitors for therapeutic use | HOFFMANN-LA ROCHE INC. (US) | 2023-01-10 | — | — | US | claimed |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | MERCK SHARP & DOHME CORP. (US) | 2022-05-31 | — | — | US | claimed |
| US-20170336420-A1 | METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASES | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2017-11-23 | — | — | US | claimed |
| EP-3215180-A1 | METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASES | Rappaport Family Institute for Research in the Medical Sciences (IL) | 2017-09-13 | — | — | EP | claimed |
| WO-2016071907-A1 | METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASES | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2016-05-12 | — | — | WO | claimed |
| US-9254285-B2 | Inhibition of choroidal neovascularization | WASHINGTON UNIVERSITY (US) | 2016-02-09 | — | — | US | claimed |
| US-20150335633-A1 | INHIBITION OF CHOROIDAL NEOVASCULARIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-26 | — | — | US | claimed |
| EP-2789347-A1 | AGENT FOR INHIBITING EXPRESSION OF NPC1L1 AND/OR LIPG MRNA AND AGENT FOR PREVENTING AND/OR TREATING OBESITY | Kowa Company, Ltd. (JP) | 2014-10-15 | — | — | EP | claimed |
| US-20140303198-A1 | AGENT FOR INHIBITING EXPRESSION OF NPC1L1 AND/OR LIPG MRNA AND AGENT FOR PREVENTING AND/OR TREATING OBESITY | KOWA COMPANY, LTD. (JP) | 2014-10-09 | — | — | US | claimed |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2013-08-01 | — | — | US | claimed |
| EP-2598158-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | Institut de Cardiologie de Montréal (CA) | 2013-06-05 | — | — | EP | claimed |
| US-20120301439-A1 | INHIBITION OF CHOROIDAL NEOVASCULARIZATION | WASHINGTON UNIVERSITY (US) | 2012-11-29 | — | — | US | claimed |
| WO-2012012870-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2012-02-02 | — | — | WO | claimed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | claimed |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2007005572-A1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | MERCK & CO., INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885 |
| US-11549142-B2 | CETP inhibitors for therapeutic use | CETP, HDLBP, APOB | CETP 1/4885NR1I2 191/4885 |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | DRD2, HTR2C, SLC18A2 | CETP 3371/4885NR1I2 560/4885 |
| US-20130197226-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | CETP 5/4885NR1I2 1684/4885 |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | PDE8B, RPS27A, PDE8A | CETP 325/4885NR1I2 4120/4885 |
| US-20140303198-A1 | AGENT FOR INHIBITING EXPRESSION OF NPC1L1 AND/OR LIPG MRNA AND AGENT FOR PREVENTING AND/OR TREATING OBESITY | LIPG, LIPA, CETP | CETP 3/4885NR1I2 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.